Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Cytomegalovirus viremia and risk of disease progression and death in HIV-positive patients starting antiretroviral therapy

Research output: Contribution to journalJournal articlepeer-review

  1. Enabling timely HIV postexposure prophylaxis access in sub-Saharan Africa

    Research output: Contribution to journalLetterpeer-review

  2. High incidence of subclinical peripheral artery disease in people with HIV

    Research output: Contribution to journalJournal articlepeer-review

  3. Risk of subarachnoid haemorrhages and aneurysms in Danish people with HIV

    Research output: Contribution to journalJournal articlepeer-review

  4. When pandemics collide: measuring the impact of coronavirus disease 2019 on people with HIV

    Research output: Contribution to journalEditorialpeer-review

  1. Efficacy and Safety of Ensovibep for Adults Hospitalized With COVID-19: A Randomized Controlled Trial

    Research output: Contribution to journalJournal articlepeer-review

  2. Personalized survival probabilities for SARS-CoV-2 positive patients by explainable machine learning

    Research output: Contribution to journalJournal articlepeer-review

  3. Observational cohort study of rilpivirine (RPV) utilization in Europe

    Research output: Contribution to journalJournal articlepeer-review

  4. Enabling timely HIV postexposure prophylaxis access in sub-Saharan Africa

    Research output: Contribution to journalLetterpeer-review

  • Laura I Levi
  • Shweta Sharma
  • Mark R Schleiss
  • Hansjakob Furrer
  • Daniel E Nixon
  • Mark Blackstad
  • Nelmary Hernandez-Alvarado
  • Dominic E Dwyer
  • Alvaro H Borges
  • H Clifford Lane
  • Jens Lundgren
  • James D Neaton
  • Jean-Michel Molina
  • INSIGHT ANRS study groups.
View graph of relations

OBJECTIVE: The aim of this study was to assess the prevalence of cytomegalovirus (CMV) viremia in HIV-positive patients starting antiretroviral therapy (ART) and to evaluate its impact on clinical outcomes.

DESIGN: A retrospective analysis of four clinical trials (INSIGHT FIRST, SMART, START, and ANRS REFLATE TB).

METHODS: Stored plasma samples from participants were used to measure CMV viremia at baseline prior to initiating ART and at visits through 1 year of follow-up after ART initiation. CMV viremia was measured centrally using a quantitative PCR assay. Within FIRST, associations of CMV viremia at baseline and through 8 months of ART were examined with a composite clinical outcome of AIDS, serious non-AIDS events, or death using Cox proportional hazards regression.

RESULTS: Samples from a total of 3176 participants, 1169 from FIRST, 137 from ANRS REFLATE TB, 54 from SMART, and 1816 from START were available with baseline CMV viremia prevalence of 17, 26, 0, and 1%, respectively. Pooled across trials, baseline CMV viremia was associated with low CD4 + T-cell counts and high HIV RNA levels. In FIRST, CMV viremia was detected in only 5% of participants between baseline and month 8. After adjustment for CD4 + T-cell count and HIV RNA levels, hazard ratios for risk of clinical outcomes was 1.15 (0.86-1.54) and 2.58 (1.68-3.98) in FIRST participants with baseline and follow-up CMV viremia, respectively.

CONCLUSION: Baseline CMV viremia in HIV-positive patients starting ART is associated with advanced infection and only persistent CMV viremia after ART initiation is associated with a higher risk of morbidity and mortality.

Original languageEnglish
JournalAIDS
Volume36
Issue number9
Pages (from-to)1265-1272
Number of pages8
ISSN0269-9370
DOIs
Publication statusPublished - 15 Jul 2022

Bibliographical note

Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.

    Research areas

  • CD4 Lymphocyte Count, Cytomegalovirus Infections/complications, Cytomegalovirus/genetics, Disease Progression, HIV Infections/complications, HIV Seropositivity/complications, Humans, RNA/therapeutic use, Retrospective Studies, Viremia/drug therapy, antiretroviral therapy, AIDS, HIV, cytomegalovirus, mortality, CD4(+) T-cell count

ID: 77955278